Table 3. Clinical laboratory data within the first 72 hours of admission from patients with COVID-19 stratified by ADAMTS13 activity level.

Characteristics		Low ADAMTS13 activity (<43%) ( n  = 33 a ) (median [IQR] or n (%))	High ADAMTS13 activity (>43%) ( n  = 69 a ) (median [IQR] or n (%))	p -Value
Age		71.0 [62.0, 80.0]	68.0 [59.0, 79.0]	0.31
Sex (Male)		22 (67)	41 (59)	0.50
Race	Black or African-American	7 (21)	28 (40)	0.09
	White	1 (3)	10 (15)	0.10
	Other/Patient declined	25 (76)	31 (45)	0.003
Ethnicity	Spanish/Hispanic/Latino	16 (49)	23 (33)	0.21
BMI (kg/m 2 )		30.9 [26.2, 32.8]	28.9 [26.9, 31.3]	0.25
Elixhauser comorbidity index		4.0 [2.0, 6.0]	4.0 [1.0, 6.0]	0.71
Mortality		23 (70)	28 (41)	0.01
Invasive ventilator use		12 (36)	11 (16)	0.04
In vivo thrombosis or ex vivo clot		5 (15)	11 (16)	>0.99
Vasopressor use		6 (18)	10 (15)	0.85
Hemodialysis or CRRT use		5 (15)	7 (10)	0.52
Anticoagulation use b		8 (24)	9 (13)	0.26
Steroid use c		10 (30)	19 (28)	0.96
Clinical laboratory values measured at time of ADAMTS13 activity (units) [reference range]
ADAMTS13 activity (%) [70–110]		34.5 [26.8, 38.6]	66.2 [50.9, 79.9]	<0.001
Schistocyte count (%) [<0.5]		2.04 [1.05, 2.85] n  = 13	0.48 [0.18, 0.68] n  = 20	0.01
Schistocyte >1%		10 (30)	1 (1)	<0.001
Ghost cell count (%)		0.39 [0.2, 0.55] n  = 13	0.27 [0.08, 2.77] n  = 20	0.07
Lactate dehydrogenase (U/L) [140–280]		555.0 [417.0, 693.0]	452.0 [283.0, 625.5]	0.03
Indirect bilirubin (mg/dL) [0.2–0.8]		0.25 [0.10, 0.40]	0.25 [0.10, 0.40]	0.61
Hemoglobin (g/dL) [12–17.5]		12.9 [11.2, 14.6]	12.5 [10.4, 14.3]	0.35
Platelet count (k/µL) [150–450]		197.0 [149.0, 270.0]	211.0 [145.0, 304.0]	0.54
Platelet trajectory d	Decrease	16 (49)	9 (13)	<0.001
	Increase	11 (33)	37 (54)	0.06
Creatinine (mg/dL) [0.84–1.21]		1.6 [0.8, 2.4]	1.1 [0.9, 2.0]	0.40
Increased creatinine trajectory d		14 (42)	16 (23)	0.08
VWF activity (Ristocetin) (%) [50–150]		352.0 [225.0, 490.0]	258.0 [200.0, 322.0]	0.04
VWF antigen (%) [50–150]		442.0 [282.0, 656.0]	346.0 [256.0, 440.0]	0.06
D-dimer (µg/mL) [<0.27]		2.6 [1.8, 13.9]	1.9 [0.8, 6.7]	0.09
Fibrin monomer (µg/mL) [<10]		5.0 [5.0, 61.8]	5.0 [5.0, 24.5]	0.29
Factor VIII activity (%) [50–150]		144.0 [112.0, 153.0] n  = 11	154.0 [98.0, 188.0] n  = 37	0.81
HMW multimer fold change from normal e		0.90 [0.68, 1.70] n  = 13	1.01 [0.87, 1.20] n  = 36	0.63
Fibrinogen (mg/dL) [200–400]		510.0 [377.5, 681.0] n  = 19	588.0 [458.8, 747.5] n  = 48	0.43
Initial clinical laboratory values measured upon admission (units) [reference range]
eGFR (mL/min/1.73 m 2 ) [90–120]		39.0 [26.0, 83.0]	56.0 [30.8, 83.4]	0.73
Aspartate Transaminase (IU/L) [8–48]		53.5 [42.5, 106.8]	44.0 [28., 69.0]	0.06
Mean platelet volume (fL) [7–12]		11.2 [10.7, 11.6]	10.7 [10.0, 11.8]	0.15
Lymphocyte (count) [1.5–4.5]		0.8 [0.6, 0.9]	1.1 [0.7, 1.5]	0.02
International normalized ratio [<1.1]		1.1 [1.0, 1.3]	1.2 [1.1, 1.3]	0.38
C-reactive protein (mg/L) [<10]		17.0 [5.3, 27.1]	13.7 [4.5, 20.4]	0.19
Troponin (ng/mL) [<0.04]		0.04 [0.01, 0.08]	0.01 [0.01, 0.04]	0.05
Pulse oximeter (%) [95–100]		92.0 [84.0, 96.0]	96.0 [91.0, 99.0]	0.03
Diastolic blood pressure (mm Hg) [60–80]		70.0 [46.0, 80.0]	72.0 [61.0, 82.0]	0.45

Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; BMI, body mass index; CRRT, continuous renal replacement therapies; eGFR, estimated glomerular filtration rate; HMW, high molecular weight; IQR, interquartile range; VWF, Von Willebrand factor.

^aUnless otherwise stated.

^bWithin 48 h prior to clot or ADAMTS13 activity measurement.

^cWithin 24 h prior to ADAMTS13 activity measurement.

^dBased on a change >10% over 1 wk period.

^e Refer to Fig. 1 .